Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial by Alexander Egle, Thomas Melchardt, Petra Obrtlíková, Lukáš Smolej, Tomáš Kozák, Michael Steurer, Johannes Andel, Sonja Burgstaller, Eva Mikušková, Liana Gercheva, Thomas Nösslinger, Tomáš Papajík, Miriam Ladická, Michael Girschikofsky, Mikuláš Hrubiško, Ulrich Jäger, Daniela Voskova, Martin Pecherstorfer, Eva Králiková, Christina Burcoveanu, Emil Spasov, Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lukas Weiss, Teresa Magnes, Lisa Pleyer, Anton Klingler, Jiří Mayer, Richard Greil

Get full text

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia by Carol Moreno, Marco Montillo, Panayiotis Panayiotidis, Maria Dimou, Adrian Bloor, Jehan Dupuis, Anna Schuh, Stefan Norin, Christian Geisler, Peter Hillmen, Michael Doubek, Marek Trněný, Petra Obrtlikova, Luca Laurenti, Stephan Stilgenbauer, Lukas Smolej, Paolo Ghia, Florence Cymbalista, Ulrich Jaeger, Kostas Stamatopoulos, Niki Stavroyianni, Patrick Carrington, Hamadi Zouabi, Veronique Leblond, Juan C. Gomez-Garcia, Martin Rubio, Roberto Marasca, Gerardo Musuraca, Luigi Rigacci, Lucia Farina, Rossella Paolini, Sarka Pospisilova, Eva Kimby, Colm Bradley, Emili Montserrat

Get full text